CA-YOKOGAWA-ELECTRIC
25.3.2022 06:02:12 CET | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that it has successfully completed a proof of concept test of technology that reduces energy consumption and stabilizes the quality of the water discharged by the Tapia Water Reclamation Facility of the Las Virgenes Municipal Water District (LVMWD), located in Los Angeles County, California. This initiative was undertaken as part of the company’s proposal to improve the performance of existing wastewater reclamation facilities in conjunction with a program sponsored by the Japan Ministry of Economy, Trade and Industry that seeks to examine opportunities for the overseas deployment of high quality energy infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324006055/en/
Water stress is an increasingly pressing issue worldwide due to the effects of climate change and the rising demand for water driven by population growth. In order to ensure stability in water resources, more and more countries are looking to make proactive use of reclaimed water. In the USA, the state of California is considering changes in regulations*1 that will allow the direct use of reclaimed water for drinking water by the end of 2023, and this is the subject of serious discussions and cooperation between the public and private sectors.
This proof of concept was conducted as part of the Pure Water Project and led by the LVMWD, whose aim is to produce potable water from highly treated wastewater in compliance with State water quality standards. Doing so required LVMWD to consider alternative technological approaches, as treating water to potable quality consumes enormous amounts of electricity and is more maintenance intensive. Yokogawa has been studying ways to address such challenges by making use of the company’s extensive process knowledge and experience in monitoring and control of industrial facilities.
Given the large fluctuations in the quality of the wastewater that flows into reclamation facilities, plant operators must take proper care while monitoring the inflow rate to ensure that the mandated water quality standards are met, and rely on their knowledge and technical expertise to make the necessary adjustments. Yokogawa applied its advanced data driven modeling for optimization (DDMO) software suite to model and then predict setpoints to optimize operations and support operator decision making while maintaining the targeted water quality at water treatment facilities.
As this proof of concept was conducted during the COVID-19 pandemic, Yokogawa used its Yokogawa Cloud platform to minimize the site activities and move site data to Japan where the DDMO software utilized real-time operational data to derive control setpoints that were sent back to operators at the Tapia Water Reclamation Facility. After conducting a multifaceted evaluation and performing a concrete verification of effectiveness, it was revealed that improvements in operational efficiency had yielded an over 10% reduction in power consumption, while meeting all water quality standards. Impressed with these results, the WateReuse Association presented Yokogawa and its partners with a 2022 Transformational Innovation award*2 .
Tsuyoshi Abe, a Yokogawa Electric vice president and head of the Marketing Headquarters, says, “Water is a public asset and a finite resource. Goal 6 of the SDGs is to ‘Ensure access to water and sanitation for all,’ and this is an important area where Yokogawa can contribute. Toward this end, the effective utilization of reclaimed water as a sustainable water source for communities is a groundbreaking approach. The efficient purification and provision of safe and secure drinking water requires the understanding of all stakeholders and a lot of revolutionary technology. In order to build a circular ecosystem for water resources and create new value, we will work to further strengthen our collaboration with partners to drive forward co-innovation, and utilizing our capabilities to measure and connect, we will fulfill our responsibilities for the future of our planet.”
*1 The California Water Boards: Regulating direct potable reuse in California
https://www.waterboards.ca.gov/drinking_water/certlic/drinkingwater/direct_potable_reuse.html
*2 WateReuse Awards for Excellence, Transformational Innovation award, presented at the 37th Annual WateReuse Symposium. Award recipients: Yokogawa Electric Corporation, Las Virgenes Municipal Water District, Carollo Engineers, the National Water Research Institute, Metropolitan Water District, Bureau of Reclamation, IOSight
https://watereuse.org/news-events/awards/past-award-winners/watereuse-award-winners-2022/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324006055/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
